Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?
- 20 December 2012
- Vol. 119 (6), 1186-1194
- https://doi.org/10.1002/cncr.27901
Abstract
BACKGROUND: Induction therapy for adults with acute lymphoblastic leukemia (ALL) is similar across essentially all regimens, comprised of vincristine, corticosteroids, and anthracyclines intensified with cyclophosphamide, asparaginase, or both. Given the lack of randomized data, to date, no regimen has emerged as standard. The authors previously evaluated cytarabine 3 g/m2 daily for 5 days with mitoxantrone 80 mg/m2 (the ALL‐2 regimen) as a novel induction regimen. Compared with historic controls, the ALL‐2 regimen was superior in terms of incidence of complete remission, failure with resistant disease, and activity in patients with Philadelphia chromosome (Ph)‐positive ALL. METHODS: The authors conducted a multicenter, prospective, randomized trial of the ALL‐2 regimen compared with a standard 4‐drug induction (the L‐20 regimen). Patients also received consolidation, maintenance therapy, and central nervous system prophylaxis. The trial accrued patients from August 1996 to October 2004. RESULTS: The median follow‐up for survivors was 7 years, and the median patient age was 43 years. Responses were evaluated in 164 patients. The treatment arms were balanced in terms of pretreatment characteristics. The frequency of complete remission for the ALL‐2 regimen versus the L‐20 regimen was 83% versus 71% (P = .06). More patients on the L‐20 arm failed with resistant disease (21% vs 8%; P = .02). Induction deaths were comparable at 9% (ALL‐2) versus 7% (L‐20). The median survival was similar; and, at 5 years, the survival rate was 33% alive on the ALL‐2 arm versus 27% on the L‐20. CONCLUSIONS: Despite superior results of induction therapy with the ALL‐2 regimen, this treatment did not improve long‐term outcomes. When coupled to the reported experience of other studies in adults with ALL, the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen. Cancer 2013. © 2012 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalJournal of Clinical Oncology, 2011
- Modern Therapy of Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2011
- Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphomaEuropean Journal of Haematology, 2009
- Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparisonBlood, 2009
- In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Blood, 2008
- Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trialsBlood, 2006
- Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trialBlood, 2004
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 2004
- Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 studyLeukemia, 2002
- Changing Concepts of Treatment in Acute LeukemiaMedical Clinics of North America, 1971